Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus

Use of Sodium-Glucose Cotransporter Type 2 Inhibitors in Older Adults with Type 2 Diabetes Mellitus

(2015) Nasser Mikhail   SOUTHERN MEDICAL JOURNAL

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

(2014) Bruce A. Perkins et al.   DIABETES CARE

Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes

(2014) A. P. Sykes et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

(2014) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis

(2014) William L. Baker et al.   Journal of the American Society of Hypertension

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Type 2 Diabetes Mellitus

(2013) Shawn Riser Taylor et al.   PHARMACOTHERAPY

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

(2013) Anita Kapur et al.   BMC Pharmacology & Toxicology

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

(2013) Elizabeth K Hussey et al.   BMC Pharmacology & Toxicology

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes

(2012) S. Mudaliar et al.   DIABETES CARE

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

(2011) R. L. Dobbins et al.   DIABETES OBESITY & METABOLISM

Biology of Human Sodium Glucose Transporters

(2011) Ernest M. Wright et al.   PHYSIOLOGICAL REVIEWS

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

(2009) J. E. Gerich   DIABETIC MEDICINE

Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

(2008) Y. Fujimori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS